From my experience, when a company begins a Phase 2 human study it issues a news release, which may even be required by the SEC.
In a Phase 2 study all participants are given the trial drug, and results are tabulated to measure its impact on the condition being trialed. If the results are sufficient a Phase 3 study may begin in which only 1/2 of the participants will receive the drug with the rest receiving a placebo.